Roswell Park Comprehensive Cancer Center: Targeted Drugs and Immunotherapies May Lower Risk of Therapy-Related Hematologic Cancers
May 30, 2020
May 30, 2020
BUFFALO, New York, May 30 -- The Roswell Park Comprehensive Cancer Center issued the following news release on May 29:
While breakthrough treatments have emerged for several cancers over the last two decades, driving striking improvements in survival and other clinical outcomes, too little is known about the risk of therapy-related hematologic cancers following targeted and immunotherapeutic approaches. In a study to be presented at the American Society of Clinical Oncology (ASCO) 2 . . .
While breakthrough treatments have emerged for several cancers over the last two decades, driving striking improvements in survival and other clinical outcomes, too little is known about the risk of therapy-related hematologic cancers following targeted and immunotherapeutic approaches. In a study to be presented at the American Society of Clinical Oncology (ASCO) 2 . . .